LONDON AstraZeneca is increasing stockpiles of those medicines in Britain and Europe that could be affected by Brexit by around 20 percent, in preparation for potential disruption if the UK crashes out of the EU without a deal.
- Bill Gates backs $30 million push for early Alzheimer's diagnostics
- U.N. says global fight against AIDS is at 'precarious point'
- China heart drug sold globally may have had impurity since 2012
- Judge rules for Trump administration in suit over family-planning program shift
- Cancer drug movie strikes nerve in China, becomes box-office hit
(Reuters Health) - Adolescents who have harmed themselves or tried to commit suicide may be less likely to do it again when they participate in an intense therapy program focused on both individual and family treatment, a U.S. study suggests.
ZURICH Swiss drugmaker Roche's hopes of recapturing lost ground in the generics-flooded influenza market got a boost after a late-stage study showed its new medicine reduced symptoms in people at high risk of complications.
AbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie's blockbuster drug Humira, in a move that will give it more near-term control over the competition.
(Reuters Health) - The 46 medicines given approval through 2017 as part of the U.S. Food and Drug Administration's Breakthrough Therapy program have often been sent to patients without a large double-blind study, direct measurement of benefit, or comparison with a placebo or existing treatment, according to a new analysis by researchers at Yale University and the Yale School of Medicine.